Journal
NATURE REVIEWS CARDIOLOGY
Volume 20, Issue 5, Pages 286-286Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41569-023-00864-4
Keywords
-
Categories
Ask authors/readers for more resources
MK-0616, an oral PCSK9 inhibitor, effectively reduces plasma LDL cholesterol levels in patients with hypercholesterolemia in a dose-dependent manner.
MK-0616, an oral inhibitor of PCSK9, safely and effectively lowers plasma levels of LDL cholesterol in a dose-dependent manner in patients with hypercholesterolaemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
